Results 161 to 170 of about 332,084 (209)

Recombinant BCG as a candidate oral vaccine vector

Research in Microbiology, 1990
Bacille Calmette-Guerin (BCG), currently the most widely used vaccine in the world, was originally administered for many years as an oral vaccine. The low frequency of serious complications, inexpensive production, and adjuvanticity make BCG an ideal candidate for a recombinant vaccine vehicle.
R G, Barletta, B, Snapper, J D, Cirillo, N D, Connell, D D, Kim, W R, Jacobs, B R, Bloom   +6 more
openaire   +2 more sources

Development of BCG As a Recombinant Vaccine Vehicle

1990
The bacille Calmette-Guerin (BCG) was developed by Dr A. Calmette and his associate Dr. C. Guerin at the Pasteur Institute in the early years of this century as a vaccine against tuberculosis. Despite enormous efforts by large numbers of experimental microbiologists of the time, the general methods for attenuating viruses and developing vaccines ...
W R, Jacobs, S B, Snapper, L, Lugosi, B R, Bloom   +3 more
openaire   +2 more sources

[Study on recombinant BCG].

Kekkaku : [Tuberculosis], 1991
For the purpose to establish the system to express foreign antigen from Mycobacterium bovis BCG. We have cloned, sequenced and expressed genes for secreting proteins, alpha antigen, MPB64, MPB57 and MPB70 from M. bovis BCG. The upstreams and structural genes were characterized. The gene for alpha antigen of Mycobacterium kansasii was also characterized.
K, Matsuo, R, Yamaguchi, A, Yamazaki, K, Terasaka, S, Nagai, H, Tasaka, C, Abe, M, Totsuka, H, Yukitake, K, Kobayashi   +9 more
openaire   +1 more source

Recombinant BCG therapy suppresses melanoma tumor growth

Annals of Surgical Oncology, 1995
Melanoma is the fastest rising cancer in the United States. Bacillus Calmette-Guerin (BCG) has been genetically engineered to actively express and secrete the cytokine interleukin-2 (IL-2). Both BCG and IL-2 have known potent antitumor and immunomodulatory properties.This recombinant BCG (rBCG 3A) has been tested as an intratumoral injection and a ...
R B, Duda, H, Yang, D D, Dooley, G, Abu-Jawdeh   +3 more
openaire   +2 more sources

Gene replacement by homologous recombination in Mycobacterium bovis BCG

Molecular Microbiology, 1995
SummaryGene replacement by homologous recombination is a powerful tool for fundamental studies of gene function, as well as allowing specific attenuation of pathogens, but has proved difficult to achieve for Mycobacterium tuberculosis. We have used a plasmid‐based test system to demonstrate the occurrence of homologous recombination in the tuberculosis
Norman, Elizabeth, Dellagostin, Odir A., McFadden, Johnjoe, Dale, Jeremy W.   +3 more
openaire   +3 more sources

The secretome of a recombinant BCG substrain reveals differences in hypothetical proteins

Vaccine, 2010
Tuberculosis remains a major human health problem worldwide, and strategies for its prevention include the generation and characterization of new recombinant vaccines containing immunodominant antigens from Mycobacterium tuberculosis. By comparing the secretomes of wild-type Mycobacterium bovis and a PstS1-recombinant M.
Mauricio, Rodríguez-Alvarez, Iliana D, Palomec-Nava, Guillermo, Mendoza-Hernández, Yolanda, López-Vidal   +3 more
openaire   +2 more sources

Recombinant BCG vaccines

Vaccine, 2001
N, Ohara, T, Yamada
openaire   +2 more sources

Expert Review of Vaccines

Expert Review of Vaccines, 2021
Dunia Rodríguez, Alex I Kanno, Luciana Leite   +2 more
exaly  

Recombinant BCG as an antigen delivery system.

Cellular and molecular biology (Noisy-le-Grand, France), 1994
BCG, an attenuated vaccine strain of Mycobacterium bovis, has been engineered for use as an antigen delivery vehicle. Various genetic and molecular biological techniques were recently developed for use in the manipulation of mycobacteria. Vectors for the expression of foreign antigens in BCG have been constructed and used to express genes from bacteria,
openaire   +1 more source

Efficacy and safety of live recombinant BCG vaccines.

Developments in biological standardization, 1995
BCG has a long history of safe use in humans and is one of the best adjuvants known. The use of newer production methods may further reduce the risk of adverse side-effects. Early results with experimental animals have shown BCG to be an effective live recombinant delivery vehicle for several foreign vaccine antigens.
M S, Hanson, G P, Bansal, S, Langermann, C K, Stover, I, Orme   +4 more
openaire   +1 more source